NKCx Histopathological outcome* within 12 months after cervix cytology in 2021 |
641 Västerbotten |
Benign | LSIL | HSIL | AIS | Cancer | Other | PAD missing | Total | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cytologi | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel |
Benign sample | 54 | 0.6% | 3 | 0.0% | . | . | . | . | . | . | . | . | 8836 | 99.4% | 8893 | 100.0% |
ASCUS | 136 | 32.2% | 51 | 12.1% | 23 | 5.5% | 1 | 0.2% | . | . | . | . | 211 | 50.0% | 422 | 100.0% |
LSIL | 90 | 29.4% | 77 | 25.2% | 32 | 10.5% | . | . | . | . | . | . | 107 | 35.0% | 306 | 100.0% |
Atypical glandular cells/AGC | 5 | 62.5% | . | . | 1 | 12.5% | 2 | 25.0% | . | . | . | . | . | . | 8 | 100.0% |
Unclear atypia | 5 | 50.0% | . | . | 4 | 40.0% | . | . | . | . | . | . | 1 | 10.0% | 10 | 100.0% |
ASC-H | 12 | 23.1% | 5 | 9.6% | 33 | 63.5% | . | . | 2 | 3.8% | . | . | . | . | 52 | 100.0% |
HSIL | 7 | 13.7% | . | . | 42 | 82.4% | . | . | 2 | 3.9% | . | . | . | . | 51 | 100.0% |
Suspected Adenocarcinom | . | . | . | . | . | . | 1 | 100.0% | . | . | . | . | . | . | 1 | 100.0% |
Totalt | 309 | 3.2% | 136 | 1.4% | 135 | 1.4% | 4 | 0.0% | 4 | 0.0% | . | . | 9155 | 94.0% | 9743 | 100.0% |
NOTE: Histopathological outcome from T83x taken into account. |
This list includes only one diagnosis (the highest ranking) per person, applies to both Cyt and Pad. |
* Harmonization of PAD codes classification between analysis registry and process registry has been carried out. PAD Class 0 (non diagnostic, unreasonable diagnosis) is excluded, and next PAD counts instead. |
The classes 2a, b, c and 3a (suspected premalignant, pre-malignant UNS, HPV, suspected malignant) are grouped into 'Other'. |
Process Registry's Class 1 (benign), 2d (LSIL) and 3b (manifest cancer) have all been introduced without exception. Some codes that occur beyond the scope of the process registry has been added to the different categories. |
Snomed codes in the category Cancer: |
---|
M80703, M81403 |